|
|||||
|
|
A pilot study of the pan‐class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer |
|
| Authors: | Ryan J. Brisson Sara Kochanny Saba Arshad Allison Dekker Jonas A. DeSouza Vassiliki Saloura Everett E. Vokes Tanguy Y. Seiwert |
| Abstract: | |
| Keywords: | advanced disease buparlisib cetuximab head and neck squamous cell carcinoma metastatic disease PI3K inhibitor recurrent disease |